ArticleDiscover oncology2026
Relationship of MicroRNA-146a rs2910164 SNP and tobacco consumption with the susceptibility of digestive system cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tobacco-driven digestive disease burden: A China-US comparative analysis, 1990-2035.Tobacco induced diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Many studies reported that microRNA (miR)-146a rs2910164 could influence the risk of digestive system cancer (DSC). The purpose of this meta-analysis was to assess a possible effectof rs2910164 C to G variant in miR-146a gene and the smoking status with risk of DSC. The EMBASE, PubMed and CBM databases were searched to retrieve eligible papers up to January 20, 2025. Finally, 11 independent case-control studies involving 17,484 subjects were included. The association of rs2910164 polymorphism and tobacco using with DSC susceptibility was evaluated. In this pooled-analysis, we found significant difference in DSC risk between tobacco users and non-tobacco users who carried rs2910164 CC/CG genotypes (OR = 1.39, 95% CI = 1.05–1.84). In addition, there was significant difference between rs2910164 polymorphism (dominant model) and DSC susceptibility in both non-tobacco (OR = 1.19, 95% CI = 1.06–1.33) and tobacco users (OR = 1.13, 95%CI = 1.01–1.26). When stratified analyses were conducted by different type of DSC, we found significant difference in esophageal squamous cell carcinoma (ESCC) risk between tobacco users and non-tobacco users who carried rs2910164 CC/CG genotypes (OR = 2.33, 95% CI = 1.55–3.50). We also found significant difference between rs2910164 (dominant model) and gastric carcinoma (GC) susceptibility in both non-tobacco (OR = 1.27, 95% CI = 1.02–1.58). In summary, the current pooled-analysis highlights that tobacco consumption significantly increases the DSC development in rs2910164 CC/CG genotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.